Looks like sojourner had his chart upside down!!! LOL
<<< What we're looking for is a run to 85 and then re-test 1.27 high >>>
Courtesy of Sojourner

You are completely out of your mind... IMO. beyond laughable delusion..

Ask Hyper-opium if that is he who is hitting the bid at 45 cents

They are hitting the 45 cent kind now..

Maybe stop talking about anonymous people and start protecting your investment against all the fake hype and hope?
Just saying...

Stop it... Your stock is supposedly on the brink of an approval that you and your ilk are portraying as a cure for all cancers and yet the stock can barely hold 45 cents and management is looting whatever is left of this OTCBB scam... Just stop it already.
Oh, and explain to me how they can get an MHRA approval without pediatric trials... I'll wait

https://www.gov.uk/guidance/procedures-for-uk-paediatric-investigation-plan-pips


All posts are my opinions only.

Trying? There have been nothing but sellers all morning.. LOL
You can buy all you want under 46 cents!!!

Maybe because they don't have anything? Ever think about that?

MHRA might be doing the same... Stock is touching 45 cents now

I don't make the news, I just read it... " T.O. declares that he has no competing interest. D.M. is an inventor on patents related to gene and cell therapy,"
9. Conclusion
This dendritic vaccine trial has several limitations. These limitations include changing the primary endpoint (OS instead of PFS), creating a new study population (recurrent glioblastoma), conducting unplanned analyses, using external controls in a design originally intended to be randomized, all changes occurring years after the trial finished enrollment. The selected external controls likely included patients with less favorable outcomes, which opposes the “fit-for-purpose” criteria usually applied in selecting external controls. Therefore, the purported survival benefit from the vaccine is unreliable. The accumulation of limitations, along with multiple changes made over nearly two decades; further hamper the reliability of the reported results. Without data sharing, those concerns cannot be alleviated. Glioblastoma is the most common primary brain tumor, and there is no valid reason to stray from the gold standard of a randomized-controlled trial with overall survival as the primary endpoint in order to change clinical practice. Dendritic cell vaccination is a very promising approach for GBM, the neuro-oncology medical community can only regret that due to the described DCVax-L trial weaknesses, we cannot draw any conclusions on potential efficacy.

4. Removing PFS as the primary endpoint: no satisfactory explanation
The authors state that they removed PFS as the primary endpoint because estimates were unreliable due to pseudoprogression, which could occur in patients receiving the vaccine product. The modified Macdonald criteria, which cannot distinguish between true progression and pseudoprogression, were used. However, pseudoprogression had already been described before the study began, [8] and the RANO working group updated the criteria in 2010 to address the issue [9]. Considering that 91.5% of patients were enrolled between 2012 and 2015, accounting for pseudoprogression in the PFS assessment could have been done with an amendment before most participants were enrolled. Lastly, one could ask why it took almost 13 years after the first enrolled patient to decide PFS was no longer a valid endpoint in this trial, which would be a major deviation from the original design. We are concerned that changes in endpoints were made because PFS was ultimately negative.
https://www.sciencedirect.com/science/article/pii/S0035378723009190

I don't think they can even get UK approval without running the Ped trial.... JMO
https://www.gov.uk/guidance/procedures-for-uk-paediatric-investigation-plan-pips

<<< Although buyout price will likely be around $15B >>>

OMG 🤯

There are none...



IMHO

External controls are industry norm.
However, there are external controls and there are NWBO scam manipulated external controls!!! 4 Years after the failed trial results!!!
Please stop thinking that NWBO is a legitimate normal industry standard concern.... it's NOT. IMO and the opinion of many others.


To conclude, stringently designed and executed prospective randomized clinical trials remain the gold standard for evaluation of efficacy of novel treatments. Control of known, but also unknown, confounders are crucial in clinical trials, and the present analyses of the DCVax-L trial offer neither. Further methodological research and definition of standards that ensure adequate scientific rigor is needed to define the possible role of externally controlled clinical trial data for retrospective analyses or within prospective clinical trials. This concerns both healthcare and regulatory decision making in (neuro-)oncology.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10076936/

Billion dollar Snake oil

"in the best best best case,,"

Learn how to read all of the words.

At 1 penny per share, maybe...

JMHO

<<< I was thinking it would be Merck for the longest time >>>>

OMG. 1,000 🤣

To conclude, stringently designed and executed prospective randomized clinical trials remain the gold standard for evaluation of efficacy of novel treatments. Control of known, but also unknown, confounders are crucial in clinical trials, and the present analyses of the DCVax-L trial offer neither. Further methodological research and definition of standards that ensure adequate scientific rigor is needed to define the possible role of externally controlled clinical trial data for retrospective analyses or within prospective clinical trials. This concerns both healthcare and regulatory decision making in (neuro-)oncology.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10076936/

References
1. Weller M, van den Bent M, Preusser M, et al.. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol. 2020; 18(3):170–186. [PMC free article] [PubMed] [Google Scholar]
2. Liau LM, Ashkan K, Brem S, et al.. Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma: a phase 3 prospective externally controlled cohort trial. JAMA Oncol. 2022; 17:e225370. doi: 10.1001/jamaoncol.2022.5370. Epub ahead of print. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
3. Liau LM, Ashkan K, Tran DD, et al.. First results on survival
from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. J Transl Med. 2018;16(1):142. [PMC free article] [PubMed] [Google Scholar]
4. Rahman R, Ventz S, McDunn J, et al.. Leveraging external data in the design and analysis of clinical trials in neuro-oncology. Lancet Oncol. 2021;22(10):e456–e465. [PMC free article] [PubMed] [Google Scholar]
5. Mishra-Kalyani PS, Amiri Kordestani L, Rivera DR, et al.. External control arms in oncology: current use and future directions. Ann Oncol. 2022;33(4):376–383. [PubMed] [Google Scholar]
6. Gilbert MR, Dignam JJ, Armstrong TS, et al.. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):699–708. [PMC free article] [PubMed] [Google Scholar]
7. Gilbert MR, Wang M, Aldape KD, et al.. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol. 2013;31(32):4085–4091. [PMC free article] [PubMed] [Google Scholar]
8. Stupp R, Taillibert S, Kanner A, et al.. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA. 2017;318(23):2306–2316. [PMC free article] [PubMed] [Google Scholar]
9. Weller M, Butowski N, Tran DD, et al.. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Lancet Oncol. 2017;18(10):1373–1385. [PubMed] [Google Scholar]
10. Stupp R, Hegi ME, Mason WP, et al.. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459–466. [PubMed] [Google Scholar]

Ummmm,...The real # is about 2-3,000 total cases per year in UK
That being said, NWBO might get 20 % of them in the best best best case,, Maybe 600
Furthermore, the 150K POUNDS goes to Advent for billing, ( NOT NWBO) and NWBO gets a 15% royalty ,... AFTER EXPENSES to Advent.
So if their expenses are 75k POUNDS, ( just estimating here) NWBO would get about 10,500 POUNDS per patient treated..
600 patients X 10,500.00 = 6,300,000.00 for a grand total of revenues in POUNDS on 600 Patients.. A far cry from a $600 Million market cap! And that is even if NICE decides to reimburse all 600 patients at 150K POUNDS per !!!
You really need to educate yourself! You have been bamboozled... IMHO and nobody else on this board seems to get it either.

*MHRA also states that NO APPROVALS will be issued WITHOUT the results from pediatric trials, which NWBO has not begun yet.


All posts are my opinions based on my DD.

<< Most neurosurgeons that deal with glioblastoma are following this trial carefully. >>

The trial is almost 10 years old!!! LOL

AstraZeneca admits for first time its Covid vaccine CAN cause rare side effect in tense legal fight with victims of 'defective' jab

https://www.dailymail.co.uk/health/article-13361271/AstraZeneca-admits-Covid-vaccine-cause-rare-blood-clotting-effect-legal-fight-victims-defective-jab.html

BZZZ. None of the above!

You do realize that potentially another perhaps Billion authorized shares are coming,... right?

IMHO

Um, the 10K shows total 2023 revenues of $1.92 Million, and that is after 10 years of C Care... WTH are you even talking about?
Nobody wants it and it is likely not getting any approvals...

IMO

Are the shareholders getting any form of these anti-dilution grants???

Looks like they have gotten their legal ducks in order to protect themselves for when things don't go as planned.
JMO

I hope you gentlemen have plenty of vaseline and KY on hand....

I fully expect management to get paid, possibly via a non dilution agreement, shareholders will get screwed... Don't get your hopes up.

JMHO

Wow... What a racket!!!

LOL.... that was the dumbest statement ever.
IBRX works! Stock is mostly held by insiders and institutions, not 99% retail bag holders!
FDA approval for Bladder cancer and lung cancer coming soon. US market and reimbursement.
NWBO has nothing but 22 employees and a corrupt management team.. IMO

I feel sorry for you

Finally something smart from you!!!

"It’s UCLA’s trial"

Can anyone post when the trials started and if, how they are proceeding?

Completed Paediatric Studies - submission, processing and assessment
"The MHRA requires data from paediatric studies before marketing approval for new medicines.
This is in addition to any requirements for registration of clinical trials and publishing of summary trial results. The results of MAH-sponsored studies in children within a period of six months from the completion of the studies. In cases where an initial MHRA appraisal indicates that an assessment is required, you will be asked to submit the paediatric data."

I guess you're the one who has trouble with basic math... Fool
Do you know what "potentially dilutive means?
Potentially dilutive securities 486,917,000
https://finance.yahoo.com/sec-filing/NWBO/0001410578-24-000133_1072379

10 K says 480 million potentially dilutive shares... Pay attention, dolt

How 'bout NEVER?

Your stock is 46 cents away from zero, and spiriing fast

It's a battle, who can sell more shares, LP or the shorts? LOL
Short interest went up about 2 million shares in the last 2 weeks
Short Interest 47,695,018

That,... I respect

IBRX drug works, and got FDA approval.. NWBO is never getting approved anywhere in my opinion - it does not work and the potential market in UK is tiny

You are way too amusing!

"a dedicated well-designed 2nd trial would have been the real answer instead of a round of intrinsically flawed data constructions. Post hoc analyses are hypothesis generating and nothing else.

To conclude, stringently designed and executed prospective randomized clinical trials remain the gold standard for evaluation of efficacy of novel treatments. Control of known, but also unknown, confounders are crucial in clinical trials, and the present analyses of the DCVax-L trial offer neither. Further methodological research and definition of standards that ensure adequate scientific rigor is needed to define the possible role of externally controlled clinical trial data for retrospective analyses or within prospective clinical trials. This concerns both healthcare and regulatory decision making in (neuro-)oncology.

Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10076936/

Also Luke Johnson. Who seems as trustworthy as gas station sushi

The one positive from this Brain Cancer malarkey, is that I can eat an entire tub of ice cream & 2 boxes of Jaffa Cakes without anyone judging me! pic.twitter.com/hANObcWVxf

— ✏️ 𝕃𝕌𝕂𝔼 (@MrLukeJohnston) April 26, 2024

Cool...
I'm in awe of your ability to be smarter and 5 steps ahead of all the smartest investors in the world who are stuck in the shabby world of buying Nasdaq and NYSE companies with promise, assets, more than 22 employees, institutional backing and marketable products - with competent CEOs who don't loot the companies for their own personal benefit while diluting current shareholders to virtual death..
Seems like you have it all figured out. GL

It’s Easier To Fool People Than To Convince Them That They’ve Been Fooled... ~ Twain
As usual , my posts are my opinions... ;)